February 7, 2018 / 2:25 PM / in 43 minutes

BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125

Reuters Staff

1 Min Read

Feb 7 (Reuters) - Auris Medical Holding AG:

* AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE

* AURIS MEDICAL HOLDING - SINGLE DOSE ANIMAL STUDY DEMONSTRATES 5 TO 35 TIMES HIGHER BIOAVAILABILITY OF INTRANASAL BETAHISTINE RELATIVE TO ORAL BETAHISTINE Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.